Agilent faces risks from general economic downturns, international market fluctuations (especially in China), customer capital spending constraints, and potential disruptions in manufacturing, supply chains, and information technology systems. Currency exchange rate fluctuations, interest rate risk, and potential tax liabilities from audits and changing regulations also pose risks. Acquisition integration and divestiture challenges, intellectual property disputes, and environmental contamination liabilities are additional concerns.

Read More

Agilent's services segment (Agilent CrossLab) shows revenue growth. The company anticipates cost savings from restructuring plans, and potentially favorable impacts from the acquisition of BIOVECTRA. Improved inventory optimization and reduced employee compensation costs are also positive factors. Favorable currency movements, and potentially favorable tax outcomes, are also mentioned as possible upside.

Read More